Zustand: Good. Good condition. A copy that has been read but remains intact. May contain markings such as bookplates, stamps, limited notes and highlighting, or a few light stains.
Sprache: Englisch
Verlag: Thomas Pubns (edition 1 Ed), 1991
ISBN 10: 0939631407 ISBN 13: 9780939631407
Anbieter: BooksRun, Philadelphia, PA, USA
Erstausgabe
Paperback. Zustand: Good. 1 Ed. It's a preowned item in good condition and includes all the pages. It may have some general signs of wear and tear, such as markings, highlighting, slight damage to the cover, minimal wear to the binding, etc., but they will not affect the overall reading experience.
Zustand: As New. Like New condition. A near perfect copy that may have very minor cosmetic defects.
Zustand: Very Good. Very Good condition. A copy that may have a few cosmetic defects. May also contain light spine creasing or a few markings such as an owner's name, short gifter's inscription or light stamp.
Zustand: Good. Good condition. A copy that has been read but remains intact. May contain markings such as bookplates, stamps, limited notes and highlighting, or a few light stains.
Paperback. Zustand: Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.
Paperback. Zustand: Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.
Paperback. Zustand: Good. No Jacket. Pages can have notes/highlighting. Spine may show signs of wear. ~ ThriftBooks: Read More, Spend Less.
Anbieter: Better World Books, Mishawaka, IN, USA
Erstausgabe
Zustand: Good. 1 Ed. Used book that is in clean, average condition without any missing pages.
Anbieter: Better World Books, Mishawaka, IN, USA
Erstausgabe
Zustand: Very Good. 1 Ed. Used book that is in excellent condition. May show signs of wear or have minor defects.
Anbieter: Better World Books, Mishawaka, IN, USA
Zustand: Good. Used book that is in clean, average condition without any missing pages.
Anbieter: Better World Books, Mishawaka, IN, USA
Zustand: Very Good. Used book that is in excellent condition. May show signs of wear or have minor defects.
Anbieter: Books From California, Simi Valley, CA, USA
Paperback. Zustand: Fine.
Anbieter: Books From California, Simi Valley, CA, USA
Paperback. Zustand: Very Good.
Signiert
Zustand: Very Good. Signed Copy . Signed/Inscribed by author on title page.
Signiert
Zustand: Very Good. Signed Copy . Signed/Inscribed by author on title page. (civil war, military history, gettysburg, pennsylvania).
Zustand: New. 2018. paperback. . . . . . Books ship from the US and Ireland.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 25,82
Anzahl: 1 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 104 pages. 8.50x5.50x0.25 inches. In Stock.
Verlag: Thomas Publications, Gettysburg, PA, 1991
Anbieter: Ground Zero Books, Ltd., Silver Spring, MD, USA
Erstausgabe
Zustand: good. First? Edition. First? Printing. 88, wraps, illus., maps, appendices, notes, index, neat ink underlining in first part of book, sticker residue on covers.
Anbieter: Phatpocket Limited, Waltham Abbey, HERTS, Vereinigtes Königreich
EUR 43,27
Anzahl: 1 verfügbar
In den WarenkorbZustand: Good. Your purchase helps support Sri Lankan Children's Charity 'The Rainbow Centre'. Ex-library, so some stamps and wear, but in good overall condition. Our donations to The Rainbow Centre have helped provide an education and a safe haven to hundreds of children who live in appalling conditions.
EUR 21,44
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. Über den AutorCindy L. Small was born and raised in Gettysburg, Pennsylvania. She earned a Bachelor of Arts degree and a Master of Science degree in Communications/Journalism from Shippensburg University. She has held positions as a.
EUR 108,14
Anzahl: 1 verfügbar
In den WarenkorbZustand: New. pp. 698.
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Zustand: Sehr gut. Zustand: Sehr gut | Seiten: 448 | Sprache: Englisch | Produktart: Bücher | Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges¿ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.
Sprache: Englisch
Verlag: Springer New York, Springer US Sep 2010, 2010
ISBN 10: 1603278311 ISBN 13: 9781603278317
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Buch. Zustand: Neu. Neuware -Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges¿ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 448 pp. Englisch.
Sprache: Englisch
Verlag: Springer New York, Springer US, 2010
ISBN 10: 1603278311 ISBN 13: 9781603278317
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges' report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.